Last reviewed · How we verify
Aricept (donepezil IR 10 mg)
Donepezil inhibits acetylcholinesterase, increasing acetylcholine levels in the brain to improve cognitive function in Alzheimer's disease.
Donepezil inhibits acetylcholinesterase, increasing acetylcholine levels in the brain to improve cognitive function in Alzheimer's disease. Used for Mild to moderate Alzheimer's disease, Cognitive decline associated with Alzheimer's disease.
At a glance
| Generic name | Aricept (donepezil IR 10 mg) |
|---|---|
| Also known as | Donepezil hydrochloride |
| Sponsor | Eisai Inc. |
| Drug class | Acetylcholinesterase inhibitor |
| Target | Acetylcholinesterase (AChE) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Donepezil is a reversible inhibitor of the enzyme acetylcholinesterase, which breaks down the neurotransmitter acetylcholine. By inhibiting this enzyme, donepezil increases acetylcholine concentration in the central nervous system, enhancing cholinergic neurotransmission. This mechanism helps improve memory, attention, and cognitive function in patients with mild to moderate Alzheimer's disease.
Approved indications
- Mild to moderate Alzheimer's disease
- Cognitive decline associated with Alzheimer's disease
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Muscle cramps
- Fatigue
- Insomnia
- Syncope
Key clinical trials
- Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's Disease (PHASE3)
- Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease (PHASE3)
- A Study Versus E2020 10mg Followed by an Open-label Extension Phase to Explore the Safety of E2020 SR 23 mg in Japanese Subjects With Severe Alzheimer's Type Dementia (PHASE2)
- Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aricept (donepezil IR 10 mg) CI brief — competitive landscape report
- Aricept (donepezil IR 10 mg) updates RSS · CI watch RSS
- Eisai Inc. portfolio CI